Clinical trial · Interventional
Measuring Oncological Value of Exercise and Statin
Syöpäpotilaan Ennusteen Parantaminen Muuttamalla syövän mikroympäristöä ja Metaboliaa Liikunnalla ja lääkkeellisesti - Measuring Oncological Value of Exercise and Statin
NCT05796973CI-TRIAL-00091469MOVESrecruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment.
Conditions
Conditions (12)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
| Metastatic Kidney Cancer | Malignant Kidney Neoplasm | CURATED_BROADER | 0.78 |
| Metastatic Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_BROADER | 0.78 |
| Metastatic Ovary Cancer | — | UNRESOLVED | — |
| Metastatic Prostate Adenocarcinoma | Prostate Adenocarcinoma | CURATED_BROADER | 0.78 |
| Metastatic Prostate Cancer | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
| Metastatic Renal Cancer | — | UNRESOLVED |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Atorvastatin | Drug | — | UNRESOLVED |
| Guided physical exercise | Behavioral | — | UNRESOLVED |
| Independent exercise | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Guided physical exercise arm
- description
- 20 patients from each type of cancer (altogether 80) are randomized to a 3 months guided physical exercise arm. At the beginning of the intervention the patients' physical condition and body composition are measured. After that an exercise program begins. All subjects participate in physical exercise program twice a week for three months. At the end of the intervention, the physical condition and body composition are measured again. During the follow-up after the intervention the patients are advised to exercise regularly. Physical condition and body composition are measured again after 6 months. Exercise activity is asked during each follow-up visit. In addition, as a separate group, 20 patients from each type of cancer (altogether 80) who are already using statin medication are randomized to this arm.
- interventionNames
- Behavioral: Guided physical exercise
- type
- EXPERIMENTAL
- label
- Atorvastatin arm
- description
- 20 patients from each type of cancer (altogether 80) are randomized to a 3 months guided physical exercise + atorvastatin (40 mg QD) arm. At the beginning of the intervention the patients' physical condition and body composition are measured. After that an exercise program begins. All subjects participate in physical exercise program twice a week for three months. At the end of the intervention, the physical condition and body composition are measured again. During the follow-up after the intervention the patients are advised to exercise regularly. Physical condition and body composition are measured again after 6 months. Exercise activity is asked during each follow-up visit.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * The patient has metastatic prostate cancer, breast cancer, ovarian cancer or kidney cancer confirmed histologically and by imaging, for which 1st-line cancer drug treatment is started * Prostate cancer: First course of docetaxel treatment or second-generation antiandrogen treatment for metastatic prostate cancer. * Breast cancer: First-line medical treatment of metastatic breast cancer regardless of hormone receptor status. * Kidney cancer: Kidney cancer, for which 1st-line cancer drug treatment is started as tki monotherapy and/or IO monotherapy or as a combination therapy. * Ovarian cancer: stage III or IV cancer for which chemotherapy treatment is started. * The patient agrees to the study and signs a written informed consent. * Adult (18 years=\>) women (breast, ovarian and kidney cancer) and men (prostate and kidney cancer) are recruited for the study. * In women, the use of a reliable contraceptive during the intervention Exclusion Criteria: * High risk of bone fractures * Inability to physical exertion and/or unsuitability for cancer drug treatment * Poor co-operation ability for psychological reasons * Active use of cholesterol-lowering drugs * Severe liver or kidney failure * Troublesome side effects that occurred in the past during cholesterol medication * Continuous use of medicinal substances that interact with atorvastatin during the study period * A special group of subjects according to the EU Clinical Trials Regulation 536/2014 (e.g. pregnant or lactating women) Exclusion criteria in patients who are already using statin medication before the study: * High risk of bone fractures * Inability to physical exertion and/or unsuitability for cancer drug treatment * Poor co-operation ability for psychological reasons * Severe liver or kidney failure * A special group of subjects according to the EU Clinical Trials Regulation 536/2014 (e.g. pregnant or lactating women)
References
Publications (0)
Data not yet available
No reference posted for this study.